Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Int J Mol Sci ; 23(2)2022 Jan 09.
Artículo en Inglés | MEDLINE | ID: mdl-35054884

RESUMEN

Thyroid cancer (TC) includes tumors of follicular cells; it ranges from well differentiated TC (WDTC) with generally favorable prognosis to clinically aggressive poorly differentiated TC (PDTC) and undifferentiated TC (UTC). Papillary thyroid cancer (PTC) is a WDTC and the most common type of thyroid cancer that comprises almost 70-80% of all TC. PTC can present as a solid, cystic, or uneven mass that originates from normal thyroid tissue. Prognosis of PTC is excellent, with an overall 10-year survival rate >90%. However, more than 30% of patients with PTC advance to recurrence or metastasis despite anti-cancer therapy; consequently, systemic therapy is limited, which necessitates expansion of improved clinical approaches. We strived to elucidate genetic distinctions due to patient-derived anti-cancer drug-sensitive or -resistant PTC, which can support in progress novel therapies. Patients with histologically proven PTC were evaluated. PTC cells were gained from drug-sensitive and -resistant patients and were compared using mRNA-Seq. We aimed to assess the in vitro and in vivo synergistic anti-cancer effects of a novel combination therapy in patient-derived refractory PTC. This combination therapy acts synergistically to promote tumor suppression compared with either agent alone. Therefore, genetically altered combination therapy might be a novel therapeutic approach for refractory PTC.


Asunto(s)
Antineoplásicos/uso terapéutico , Resistencia a Antineoplásicos , Regulación Neoplásica de la Expresión Génica , Cáncer Papilar Tiroideo/tratamiento farmacológico , Adulto , Anciano , Animales , Femenino , Humanos , Masculino , Ratones , Persona de Mediana Edad , Paclitaxel/uso terapéutico , Compuestos de Fenilurea/uso terapéutico , Pronóstico , Quinolinas/uso terapéutico , RNA-Seq , Sorafenib/uso terapéutico , Cáncer Papilar Tiroideo/genética , Cáncer Papilar Tiroideo/fisiopatología , Ensayos Antitumor por Modelo de Xenoinjerto
2.
Math Biosci Eng ; 16(6): 8069-8091, 2019 09 05.
Artículo en Inglés | MEDLINE | ID: mdl-31698655

RESUMEN

Hashimoto's thyroiditis (HT) is an autoimmune disorder that drives the function of thyroid gland to the sequential clinical states:euthyroidism (normal condition), subclinical hypothyroidism (asymptomatic period) and overt hypothyroidism (symptomatic period). In this disease, serum thyroidstimulating hormone (TSH) levels increase monotonically, stimulating the thyroid follicular cells chronically and initiating benign (non-cancerous) thyroid nodules at various sites of the thyroid gland. This process can also encourage growth of papillary thyroid microcarcinoma. Due to prolonged TSH stimulation, thyroid nodules may grow and become clinically relevant without the administration of treatment by thyroid hormone replacement. Papillary thyroid cancer (80% of thyroid cancer) whose incidence is increasing worldwide, is associated with Hashimoto's thyroiditis. A stochastic model is developed here to produce the statistical distribution of thyroid nodule sizes and growth by taking serum TSH value as the continuous input to the model using TSH values from the output of the patientspecific deterministic model developed for the clinical progression of Hashimoto's thyroiditis.


Asunto(s)
Enfermedad de Hashimoto/complicaciones , Cáncer Papilar Tiroideo/complicaciones , Neoplasias de la Tiroides/complicaciones , Tiempo de Tratamiento , Biopsia con Aguja Fina , Simulación por Computador , Progresión de la Enfermedad , Enfermedad de Hashimoto/fisiopatología , Humanos , Hipotálamo/patología , Incidencia , Modelos Teóricos , Receptores de Tirotropina/metabolismo , Riesgo , Procesos Estocásticos , Tiroglobulina/metabolismo , Cáncer Papilar Tiroideo/fisiopatología , Glándula Tiroides/patología , Neoplasias de la Tiroides/fisiopatología , Nódulo Tiroideo/complicaciones , Nódulo Tiroideo/fisiopatología , Tirotropina/metabolismo , Tiroxina/metabolismo , Triyodotironina/metabolismo
3.
J Trace Elem Med Biol ; 55: 190-195, 2019 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-31345357

RESUMEN

BACKGROUND: The etiology of papillary thyroid carcinoma (PTC) is unknown and some literature data support the hypothesis that heavy metals, as endocrine disrupters, could play a major role in the pathogenesis of thyroid cancer. This study aimed to estimate the content of selected toxic and essential trace metals (Mn, Co, Ni, Cu, Zn, As, Se, Cd, Pb, Th, and U), as well as the selected ratio's (Cu/Zn and Cd/Se) in the malignant thyroid tissues according to sex, age, smoking habits, familial history of any thyroid disease, pathohistological (PH) types of PTC, tumor size, the existence of a thyroid capsular invasion, intrathyroid tumor dissemination, retrosternal thyroid growth, and TNM progress of PTC. METHODS: The study included 66 patients with PTC (women/men ratio = 46/20, mean age: 54 ± 14 years). A comparative analysis was made by collecting the healthy thyroid tissues (HTTs) of the same patients, making the total number of samples 132. All trace metals were quantified by inductively coupled plasma-mass spectrometry (ICP-MS). RESULTS: Metals that significantly separated papillary thyroid tissues (PTTs) from the HTTs were Cd, U and Se (p < 0.05). The obtained negative correlation between Cd and Se in the PTTs could explain extrusion of essential Se caused by increased content of Cd. Only Cd had an influence on the retrosternal thyroid growth, while the essential metals (Mn, Co, and Zn) had an influence on thyroid capsular invasion. CONCLUSION: It was found that Cd act as the main endocrine disrupter, which could highlight its role in the etiology of PTC. Considering that the Cd/Se ratio significantly separated two studied groups and had an influence on the retrosternal thyroid growth, its altered content could contribute to the better understanding of the molecular basis for pathophysiological changes in the PTC.


Asunto(s)
Cadmio/análisis , Cadmio/toxicidad , Disruptores Endocrinos/análisis , Disruptores Endocrinos/toxicidad , Selenio/análisis , Cáncer Papilar Tiroideo/inducido químicamente , Cáncer Papilar Tiroideo/fisiopatología , Femenino , Humanos , Masculino , Espectrometría de Masas , Persona de Mediana Edad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA